Qualigen Therapeutics, Inc. announced key leadership changes, appointing Jerry Wang as Co-CEO and Koti Meka as CFO. Three new directors were added to the Board, including Kevin Chen and Chad Chen. Jay Sheng was named Chairman of the Audit Committee. The company also changed auditors, engaging MGO while Withum resigned. The moves aim to enhance transparency and growth strategy. These changes are seen as a positive step forward for Qualigen Therapeutics, positioning them for long-term success. The company is focused on developing innovative oncology and immunology therapeutics, with plans for crypto and web3 initiatives.

Read more at GlobeNewswire: Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives,